MDPI and ACS Style
Clausen, M.M.; Carlsen, E.A.; Christensen, C.; Madsen, J.; Brandt-Larsen, M.; Klausen, T.L.; Holm, S.; Loft, A.; Berthelsen, A.K.; Kroman, N.;
et al. First-in-Human Study of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET for Integrin αvβ3 Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability. Diagnostics 2022, 12, 851.
https://doi.org/10.3390/diagnostics12040851
AMA Style
Clausen MM, Carlsen EA, Christensen C, Madsen J, Brandt-Larsen M, Klausen TL, Holm S, Loft A, Berthelsen AK, Kroman N,
et al. First-in-Human Study of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET for Integrin αvβ3 Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability. Diagnostics. 2022; 12(4):851.
https://doi.org/10.3390/diagnostics12040851
Chicago/Turabian Style
Clausen, Malene Martini, Esben Andreas Carlsen, Camilla Christensen, Jacob Madsen, Malene Brandt-Larsen, Thomas Levin Klausen, Søren Holm, Annika Loft, Anne Kiil Berthelsen, Niels Kroman,
and et al. 2022. "First-in-Human Study of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET for Integrin αvβ3 Imaging in Patients with Breast Cancer and Neuroendocrine Neoplasms: Safety, Dosimetry and Tumor Imaging Ability" Diagnostics 12, no. 4: 851.
https://doi.org/10.3390/diagnostics12040851